UniQure said it plans to seek UK approval of its Huntington’s gene therapy AMT-130 after a positive meeting with UK regulators. The company pointed to three-year analyses from ongoing studies in the US and Europe showing apparent slowing of disease progression at the highest dose tested, while noting that the FDA previously demanded a new sham-controlled trial before considering approval.